The
ATG10, which is an autophagic E2 enzyme, interacts with
ATG7 to receive an ubiquitin-like molecule
ATG12, and is also involved in the
ATG12–
ATG5 conjugation reaction.
37 The
ATG10 has been shown to play a role in the proliferation and invasion of cancer cells
38 and an association of genetic variants in
ATG10 with breast cancer has been reported.
39 A possible role of
ATG10 in autoimmune or autoinflammatory disease has not yet been reported. During our genome-wide association studies (GWAS) for VKH, we discovered 2 SNPs in
ATG10 that may confer risk to VKH (5 × 10
−8 <
P < 0.05).
30 Although these SNPs did not reach the GWAS
P-value threshold, we decided to include them in the current study with a larger patient sample size. The protective effect of the AA genotype of
ATG10/rs4703863 could be confirmed but is modest, whereby 60% of controls and 50% of VKH patients carry this genotype. Furthermore, due to the very low frequency of the CC genotype both in patients and controls, we could not detect a positive predisposing effect of the CC genotype of
ATG10/rs4703863 in VKH (Pc > 0.05, OR = 1.246); however, we did observe that the C allele of
ATG10/rs4703863 conferred risk to VKH (Pc = 7.06 × 10
−5, OR = 1.342). How
ATG10 affects predisposition to VKH is not clear, and functional studies did not show an effect of the
ATG10 genotypes on mRNA expression by PBMCs. Comparison of
ATG10 mRNA expression between active VKH patients and healthy controls also did not show a significant difference, and further studies are needed to elucidate the exact role of
ATG10 in the development of VKH.